In the Preliminary Communication by Londres HD, Armada JJ, Martínez AH et al., ‘Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment’ published in the May 2022 issue of Immunotherapy (Immunotherapy 14(7), 521–530 [2022]), the following corrections have been added in the results and discussion for the clarity of the manuscript.
Results
Original article displayed as:
“Overall, eight of 12 severe patients (66.7%) who received CIGB-258 recovered, compared with 17 of 19 individuals (89.5%) treated with nimotuzumab plus steroids, anticoagulant and antibiotics”.
Correction of article displayed as:
“Overall, eight of 12 severe patients (66.7%) who received the combination of nimotuzumab + SOC + CIGB-258 recovered, while 17 of 19 individuals (89.5%) treated with nimotuzumab plus steroids, anticoagulant and antibiotics”.
Discussion
Original article displayed as:
“Control patients received standard treatment according to the national protocol, but not nimotuzumab”.
Correction of article displayed as:
“Control patients received standard treatment according to the national protocol, but not nimotuzumab or any other immunomodulatory drug, including CIGB-258”.
The authors and the editors of Immunotherapy would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.